[go: up one dir, main page]

PE20060555A1 - Derivados de pirrol-oxindol como moduladores del receptor de progesterona - Google Patents

Derivados de pirrol-oxindol como moduladores del receptor de progesterona

Info

Publication number
PE20060555A1
PE20060555A1 PE2005000784A PE2005000784A PE20060555A1 PE 20060555 A1 PE20060555 A1 PE 20060555A1 PE 2005000784 A PE2005000784 A PE 2005000784A PE 2005000784 A PE2005000784 A PE 2005000784A PE 20060555 A1 PE20060555 A1 PE 20060555A1
Authority
PE
Peru
Prior art keywords
progesterone receptor
pirrol
pyrrol
alkyl
receptor modulators
Prior art date
Application number
PE2005000784A
Other languages
English (en)
Inventor
Michael Anthony Marella
Casey Cameron Mccomas
Jay Edward Wrobel
Andrew Fensome
Edward George Melenski
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34993110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060555A1 publication Critical patent/PE20060555A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION QUE COMPRENDE UN COMPUESTO ANTAGONISTA DEL RECEPTOR DE PROGESTERONA DERIVADO DE PIRROL-OXINDOL DE FORMULA I, DONDE R1 ES H, ALQUENILO C3-C6, ALQUINILO C3-C6, ENTRE OTROS; R2 Y R3 SON H, ALQUILO, ENTRE OTROS; R4, R5, R6 Y R8 SON H; R7 ES H O ALQUILO; R9 ES H, ALQUILO, ENTRE OTROS; RA ES ALQUILO O ALQUILO SUSTITUIDO. SON COMPUESTOS PREFERIDOS: 1-METIL-5-(2'-OXO-1',2'-DIHIDROESPIRO[CICLOBUTAN-1,3'-INDOL]-5'-IL)-1H-PIRROL-2-CARBONITRILO, 1-METIL-5-(2-OXO-2,3-DIHIDRO-1H-INDOL-5-IL)-1H-PIRROL-2-CARBONITRILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN KIT. DICHOS COMPUESTOS SON UTILES EN LA ANTICONCEPCION, EN EL TRATAMIENTO DE REEMPLAZO HORMONAL, EN EL TRATAMIENTO DE ENFERMEDADES NEOPLASICAS, ENTRE OTROS
PE2005000784A 2004-08-09 2005-07-06 Derivados de pirrol-oxindol como moduladores del receptor de progesterona PE20060555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59990004P 2004-08-09 2004-08-09

Publications (1)

Publication Number Publication Date
PE20060555A1 true PE20060555A1 (es) 2006-06-26

Family

ID=34993110

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000784A PE20060555A1 (es) 2004-08-09 2005-07-06 Derivados de pirrol-oxindol como moduladores del receptor de progesterona

Country Status (20)

Country Link
US (1) US20060030615A1 (es)
EP (1) EP1778222A1 (es)
JP (1) JP2008509216A (es)
KR (1) KR20070039925A (es)
CN (1) CN101001625A (es)
AR (1) AR049708A1 (es)
AU (1) AU2005277879A1 (es)
BR (1) BRPI0514196A (es)
CA (1) CA2573310A1 (es)
EC (1) ECSP077236A (es)
GT (1) GT200500183A (es)
IL (1) IL180955A0 (es)
MX (1) MX2007001614A (es)
NO (1) NO20070723L (es)
PA (1) PA8638701A1 (es)
PE (1) PE20060555A1 (es)
RU (1) RU2007101304A (es)
TW (1) TW200605882A (es)
WO (1) WO2006023107A1 (es)
ZA (1) ZA200701156B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
CN1980676A (zh) 2004-07-07 2007-06-13 惠氏公司 周期性黄体酮方案及试剂盒
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
CN101166532B (zh) 2005-04-28 2011-06-22 惠氏公司 微粒化的他那普戈特、组合物及其制备方法
US8343965B2 (en) * 2005-04-28 2013-01-01 Wyeth Llc Compositions containing micronized tanaproget prepared by wet granulation
ES2340518T3 (es) * 2005-04-28 2010-06-04 Wyeth Llc Tanaproget micronizado y composiciones que lo contienen.
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070220A1 (es) 2005-07-29 2007-03-19 Wyeth Corp Proceso para la sintesis de moduladores del receptor de progesterona
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
US7414142B2 (en) 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
US7319152B2 (en) * 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US20070066628A1 (en) * 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
US20070213526A1 (en) * 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
US20080051585A1 (en) * 2006-08-17 2008-02-28 Wyeth Process for the preparation of indolin-2-one derivatives useful as PR modulators
CN101631546A (zh) 2006-10-12 2010-01-20 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
TW200848021A (en) * 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor
US20080312306A1 (en) * 2007-06-15 2008-12-18 Wyeth Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile
US20080319204A1 (en) * 2007-06-25 2008-12-25 Wyeth Process for the synthesis of progesterone receptor modulators
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AU2009303468B2 (en) 2008-10-17 2014-08-28 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
NZ599334A (en) 2009-10-14 2014-03-28 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462032B1 (en) * 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
TW200605882A (en) 2006-02-16
US20060030615A1 (en) 2006-02-09
BRPI0514196A (pt) 2008-06-03
NO20070723L (no) 2007-05-07
CA2573310A1 (en) 2006-03-02
WO2006023107A1 (en) 2006-03-02
ZA200701156B (en) 2008-08-27
GT200500183A (es) 2006-04-10
AU2005277879A1 (en) 2006-03-02
MX2007001614A (es) 2007-04-10
CN101001625A (zh) 2007-07-18
JP2008509216A (ja) 2008-03-27
ECSP077236A (es) 2007-03-29
KR20070039925A (ko) 2007-04-13
AR049708A1 (es) 2006-08-30
RU2007101304A (ru) 2008-09-20
EP1778222A1 (en) 2007-05-02
PA8638701A1 (es) 2006-06-02
IL180955A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20060486A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
ES2220529T3 (es) Dibenzopiranos utiles como antagonistas del receptor de los glucocorticoides, en el tratamiento de la diabetes.
PE20081504A1 (es) Compuestos de biciclocarboxiamida sustituidos
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20040168A1 (es) Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
AR035783A1 (es) Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3
PE20050756A1 (es) Heterociclicos azabiciclicos como moduladores del receptor cannabinoide
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20020532A1 (es) Derivados de naftaleno como agonistas del receptor canabinoide
PE20090279A1 (es) Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FC Refusal